-
Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany’s DIGA
Sep 9, 2025, 16:22 PM -
Building Risk-Sharing Agreements in Chile: Feasibility and Policy Options
Sep 9, 2025, 16:22 PM -
Correlation Between Ultra-Orphan Drug Costs Cost-Effectiveness Metrics and Disease Prevalence
Sep 9, 2025, 16:22 PM -
Instrumental Variable Treatment Effects Estimation: A Simulation Comparison of Instrumental Variables and OLS Approaches
Sep 9, 2025, 16:22 PM -
Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries
Sep 9, 2025, 16:22 PM -
Trends in Reimbursement Agreements for Innovative Orphan and Oncological Medicines in Spain 2020-2025
Sep 9, 2025, 16:22 PM -
The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study
Sep 9, 2025, 16:22 PM -
Applying G-methods to Account for Treatment Switching in Postmarketing Effectiveness Evaluation: A Case Study of GLP-1 Receptor Agonists for Diabetic Kidney Disease
Sep 9, 2025, 16:22 PM -
Cost-Savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates
Sep 9, 2025, 16:22 PM -
Factors Impacting GKV Rebates for Orphan Drugs (OD) in Germany: A Decision Analysis Using the CRA RADAR Database
Sep 9, 2025, 16:22 PM -
Patient Perspectives on Disease Experiences and Value of Real-Time Self-Reported Symptom and Treatment Monitoring in Locally Advanced and Metastatic Breast Cancer
Sep 9, 2025, 16:22 PM -
Impact of Dupilumab on Mental Health Service Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study
Sep 9, 2025, 16:22 PM -
Systematic Review of Doubly Robust Methods for Population-Adjusted Indirect Comparisons
Sep 9, 2025, 16:22 PM -
Focus on Two Years of Economic Opinions on Solid Cancers (2023-2024): What Are the Specific Features vs. 2021-2022?
Sep 9, 2025, 16:22 PM -
Is Europe and European Evidence Development an Afterthought in Pharmaceutical Early Stage Development Decisions? An Exploratory Qualitative Survey
Sep 9, 2025, 16:22 PM -
Evidence-Driven Simulated Agents to Train Reinforcement Learning for Personalization in mHealth Interventions
Sep 9, 2025, 16:22 PM -
The Impact of Using England Real-World Evidence to Establish the NICE Severity Modifier in Metastatic Urothelial Carcinoma (MUC)
Sep 9, 2025, 16:22 PM -
Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews
Sep 9, 2025, 16:22 PM -
Pharmacoeconomic and Healthcare Aspects of the TDM-Guided Decisions on Biological Treatment of Inflammatory Diseases: Systematic Review of International Evidence
Sep 9, 2025, 16:22 PM -
How Publication Bias May Overestimate the Risk of Serious Adverse Events Associated With Bisphosphonate Use
Sep 9, 2025, 16:22 PM
